Oncology Institute Inc’s recent filing unveils that its Chief Executive Officer Virnich Daniel acquired Company’s shares for reported $23584.0 on Mar 26 ’25. In the deal valued at $1.04 per share,22,640 shares were bought. As a result of this transaction, Virnich Daniel now holds 724,363 shares worth roughly $2.22 million.
Then, Podnos Yale bought 9,056 shares, generating $9,434 in total proceeds. Upon buying the shares at $1.04, the Chief Medical Officer now owns 79,049 shares.
Before that, Pacala Mark L bought 90,562 shares. Oncology Institute Inc shares valued at $94,338 were divested by the Director at a price of $1.04 per share. As a result of the transaction, Pacala Mark L now holds 224,971 shares, worth roughly $0.69 million.
BTIG Research initiated its Oncology Institute Inc [TOI] rating to a Buy in a research note published on May 15, 2025; the price target was $7. Guggenheim began covering TOI with “Buy” recommendation on September 14, 2022. Jefferies started covering the stock on August 15, 2022. It rated TOI as “a Buy”.
Price Performance Review of TOI
On Monday, Oncology Institute Inc [NASDAQ:TOI] saw its stock jump 2.34% to $3.06. Over the last five days, the stock has gained 20.00%. Oncology Institute Inc shares have risen nearly 890.29% since the year began. Nevertheless, the stocks have risen 347.37% over the past one year. While a 52-week high of $3.50 was reached on 04/24/25, a 52-week low of $0.13 was recorded on 01/10/25.
How much short interest is there in Oncology Institute Inc?
A steep rise in short interest was recorded in Oncology Institute Inc stocks on 2025-04-30, growing by 0.19 million shares to a total of 1.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 1.29 million shares. There was a rise of 12.65%, which implies that there is a positive sentiment for the stock.
